TDZD 8
Chemical Name: 2-Methyl-4-(phenylmethyl)-1,2,4-thiadiazolidine-3,5-dione
Purity: ≥98%
Biological Activity
TDZD 8 is a selective non-ATP competitive inhibitor of GSK 3β (IC50 = 2 μM); thiadiazolidinone deriviative. Does not inhibit Cdk-1/cyclin B, CK-II, PKA or PKC at >100 μM. Reduces severity of L-dopa-induced dyskinesia in a Parkinson's disease in vivo model.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
Martinez et al.
J.Med.Chem., 2002;45:1292 -
Inhibition of Glycogen Synthase Kinase-3β (GSK-3�) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Xie et al.
Sci.Rep., 2016;6:23527
Product Datasheets
Citation for TDZD 8
The citations listed below are publications that use Tocris products. Selected citations for TDZD 8 include:
1 Citation: Showing 1 - 1
-
Glycogen synthase kinase-3 inhibition rescues sex-dependent contextual fear memory deficit in human immunodeficiency virus-1 transgenic mice.
Authors: Coleen M Et al.
Br J Pharmacol 2020;177:5658-5676
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for TDZD 8
There are currently no reviews for this product. Be the first to review TDZD 8 and earn rewards!
Have you used TDZD 8?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
